TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Benzinga Logo Benzinga By Globe Newswire
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

MapLight Therapeutics completed its initial public offering of 16,962,500 shares at $17.00 per share, raising $296.3 million. The company is a clinical-stage biopharmaceutical firm focused on central nervous system disorders, with a lead product candidate ML-007C-MA for schizophrenia and Alzheimer's disease psychosis.

Insights
VMC   neutral

Listed as a top holding with $204.8 million allocation, no specific performance details provided


MPLT   positive

Successfully completed IPO, raised significant capital ($296.3M), trading on Nasdaq, advancing clinical-stage drug development for neurological disorders